Trial Profile
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Dasatinib (Primary) ; Prednisone (Primary) ; Mercaptopurine; Methotrexate; Methotrexate; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Updated results of median follow-up, 4.3 years, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 23 Sep 2023 Planned End Date changed from 7 Oct 2023 to 21 Sep 2024.
- 09 Sep 2023 Planned End Date changed from 2 Sep 2023 to 7 Oct 2023.